ASLAN PHARMACEUTICALS TEMPORARILY PAUSES RECRUITMENT OF NEW PATIENTS INTO ASLAN004 STUDY DUE TO COVID-19

ASLAN intends to resume screening as soon as government restrictions are lifted and is taking steps to open sites in Australia to accelerate recruitment

Study remains on track to report interim, unblinded data from all 3 dose cohorts in MAD study in 3Q 2020

Singapore, 13 April 2020 – ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that recruitment of new patients into its randomised, double-blind, placebo-controlled multiple ascending dose (MAD) study of ASLAN004 in moderate to severe atopic dermatitis has been paused in light of recently imposed government restrictions in Singapore to contain the spread of the coronavirus disease (COVID-19). ASLAN does not currently expect these measures to materially affect the projected timelines for the readout of interim, unblinded data later this year.

ASLAN was recruiting patients into the second of three dose cohorts. Clinical studies in Singapore, other than those related to COVID-19, have paused recruitment in line with the recent restrictions on movement of the public to contain the spread of COVID-19. ASLAN intends to resume screening of new patients as soon as these restrictions are lifted, which is currently due to take place on 4 May 2020.

In parallel, ASLAN has identified several clinical sites in Australia, which could join the study mid-year to accelerate recruitment.

Dr Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals, said: “It is vital that hospitals and other medical services focus their limited resources on helping the millions affected by COVID-19. We are hopeful that by taking these necessary measures, the outbreak will soon be brought under control and we can resume our studies safely.”